Shenzhen Kangtai Biological Products Co Ltd

Shenzhen Kangtai Biological Products Co., Ltd. is a China-based company that researches, develops, produces, and sells human vaccines. Its portfolio includes pneumococcal conjugate, varicella, hepatitis B, and rabies vaccines, as well as combined vaccines for diphtheria, tetanus, pertussis, and Haemophilus influenzae type B. The company also develops vaccines for measles, mumps, rubella, influenza, and polio, and provides freight, warehousing, and pharmaceutical technology services. Founded in 1992, it is headquartered in Shenzhen and exports its products internationally.

300601.CS▼

Kangtai Bio Releases 2026 Interim Report with Net Profit of 50.3861 Million Yuan

Kangtai Bio released its 2026 interim report, with net profit attributable to the parent company of 50.3861 million yuan. The company's total operating revenue was 1.273 billion yuan, down 8.55% from the same period last year. Net cash inflow from operating activities was 24.7039 million yuan, down 67.32% year-on-year. The company's latest asset-liability ratio was 30.64%, gross margin was 71.33%, ROE was 0.52%, and diluted earnings per share was 0.05 yuan.

300601.CS ▼

Jiemian·28dRead more →